JP2010504079A5 - - Google Patents

Info

Publication number

JP2010504079A5

JP2010504079A5 JP2009516634A JP2009516634A JP2010504079A5 JP 2010504079 A5 JP2010504079 A5 JP 2010504079A5 JP 2009516634 A JP2009516634 A JP 2009516634A JP 2009516634 A JP2009516634 A JP 2009516634A JP 2010504079 A5 JP2010504079 A5 JP 2010504079A5

Authority

JP

Japan

Prior art keywords

breast cancer

administration

subject

neu

her2

Prior art date

2007-06-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 206010006187 Breast cancer Diseases 0.000 claims description 17
• 208000026310 Breast neoplasm Diseases 0.000 claims description 17
• 238000000034 method Methods 0.000 claims description 8
• 108090000623 proteins and genes Proteins 0.000 claims description 6
• 230000002950 deficient Effects 0.000 claims description 3
• 230000001105 regulatory effect Effects 0.000 claims description 3
• 239000000203 mixture Substances 0.000 claims 8
• 150000003839 salts Chemical class 0.000 claims 4
• MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims 2
• 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 239000002246 antineoplastic agent Substances 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 238000002512 chemotherapy Methods 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 102000015694 estrogen receptors Human genes 0.000 claims 2
• 108010038795 estrogen receptors Proteins 0.000 claims 2
• 229940116978 human epidermal growth factor Drugs 0.000 claims 2
• 238000007918 intramuscular administration Methods 0.000 claims 2
• 238000001990 intravenous administration Methods 0.000 claims 2
• GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims 2
• 238000007911 parenteral administration Methods 0.000 claims 2
• 102000003998 progesterone receptors Human genes 0.000 claims 2
• 108090000468 progesterone receptors Proteins 0.000 claims 2
• 238000001959 radiotherapy Methods 0.000 claims 2
• 238000007920 subcutaneous administration Methods 0.000 claims 2
• 238000001356 surgical procedure Methods 0.000 claims 2
• 238000011282 treatment Methods 0.000 claims 2
• NZBUMQONDVMPDO-UHFFFAOYSA-N 2-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=CC([N+]([O-])=O)=C1I NZBUMQONDVMPDO-UHFFFAOYSA-N 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 7
• 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 7
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 5
• 239000012661 PARP inhibitor Substances 0.000 description 3
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 108700020463 BRCA1 Proteins 0.000 description 1
• 102000036365 BRCA1 Human genes 0.000 description 1
• 101150072950 BRCA1 gene Proteins 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1